SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance

SHMT2 促进神经胶质瘤细胞在缺血状态下存活,但依赖于甘氨酸清除率

阅读:4
作者:Dohoon Kim, Brian P Fiske, Kivanc Birsoy, Elizaveta Freinkman, Kenjiro Kami, Richard L Possemato, Yakov Chudnovsky, Michael E Pacold, Walter W Chen, Jason R Cantor, Laura M Shelton, Dan Y Gui, Manjae Kwon, Shakti H Ramkissoon, Keith L Ligon, Seong Woo Kang, Matija Snuderl, Matthew G Vander Heiden, D

Abstract

Cancer cells adapt their metabolic processes to support rapid proliferation, but less is known about how cancer cells alter metabolism to promote cell survival in a poorly vascularized tumour microenvironment. Here we identify a key role for serine and glycine metabolism in the survival of brain cancer cells within the ischaemic zones of gliomas. In human glioblastoma multiforme, mitochondrial serine hydroxymethyltransferase (SHMT2) and glycine decarboxylase (GLDC) are highly expressed in the pseudopalisading cells that surround necrotic foci. We find that SHMT2 activity limits that of pyruvate kinase (PKM2) and reduces oxygen consumption, eliciting a metabolic state that confers a profound survival advantage to cells in poorly vascularized tumour regions. GLDC inhibition impairs cells with high SHMT2 levels as the excess glycine not metabolized by GLDC can be converted to the toxic molecules aminoacetone and methylglyoxal. Thus, SHMT2 is required for cancer cells to adapt to the tumour environment, but also renders these cells sensitive to glycine cleavage system inhibition.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。